Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Director | October 12, 2026 | October 13, 2026 |
| CYPHERPUNK TECHNOLOGIES INC.CYPH · Entity 6392 | Director | September 23, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,252 |
Reported balance
After 2026-10-12 transaction · row 1
1 source rowRow 1 · 2026-10-12 · Grant · Acquired 389 · Balance 19,252 F1: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
CYPHERPUNK TECHNOLOGIES INC.
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 118,750 |
Reported balance
After 2026-09-23 transaction · row 1
1 source rowRow 1 · 2026-09-23 · Sale · Disposed 50,000 · Balance 118,750 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the settlement of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 13, 2026 21:12 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 389 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-420641 · ownership.xml · nonDerivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,252 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 22:13 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | SaleCommon Stock | 50,000 | $3.86 | $193,000.00 |
DisclosureSEC source: 0001104659-26-111061 · tm2626176-2_4seq1.xml · nonDerivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,750 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the settlement of restricted stock units. Read SEC document |
| July 10, 2026 Filed Jul 10, 2026 23:40 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 766 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-301165 · ownership.xml · nonDerivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,863 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 01:56 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-080494 · tm2619727-4_4seq1.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"). The RSUs were issued under the Company's 2025 Equity Incentive Plan for no consideration. F2 · derivative.exercise_date: The RSUs will vest on June 15, 2027. Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock no later than the fifteenth (15th) day of the third (3rd) calendar month following the calendar year in which the date of grant occurs. F2 · derivative.expiration_date: The RSUs will vest on June 15, 2027. Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock no later than the fifteenth (15th) day of the third (3rd) calendar month following the calendar year in which the date of grant occurs. Read SEC document |
| April 10, 2026 Filed Apr 11, 2026 00:51 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 1,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-151626 · ownership.xml · nonDerivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,097 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:10 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 23,742 | Not disclosed Strike: $5.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120223 · ownership.xml · derivative · entry 6 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:10 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 23,742 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120223 · ownership.xml · derivative · entry 5 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:10 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 10,362 | Not disclosed Strike: $17.28 | Not disclosed |
DisclosureSEC source: 0001193125-26-120223 · ownership.xml · derivative · entry 4 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,362 shares Expires 2032-05-11 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:10 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 10,362 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120223 · ownership.xml · derivative · entry 3 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,362 Underlying: Common Stock · 10,362 shares Expires 2032-05-11 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:10 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 24,999 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001193125-26-120223 · ownership.xml · derivative · entry 2 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,999 shares Expires 2031-04-29 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:10 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 24,999 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120223 · ownership.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,999 Underlying: Common Stock · 24,999 shares Expires 2031-04-29 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:58 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Exercise / conversionRestricted Stock Units · Derivative | 94,050 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-029637 · tm269084-4_4seq1.xml · derivative · entry 4 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock. F4 · derivative.exercise_date: The December 2025 RSUs vested at issuance on their grant date. F4 · derivative.expiration_date: The December 2025 RSUs vested at issuance on their grant date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:58 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Exercise / conversionRestricted Stock Units · Derivative | 74,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-029637 · tm269084-4_4seq1.xml · derivative · entry 3 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock"). F3 · derivative.exercise_date: The November 2025 RSUs vested at issuance on their grant date. F3 · derivative.expiration_date: The November 2025 RSUs vested at issuance on their grant date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:58 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Exercise / conversionCommon Stock | 94,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-029637 · tm269084-4_4seq1.xml · nonDerivative · entry 2 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock. F2 · price: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:58 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Exercise / conversionCommon Stock | 74,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-029637 · tm269084-4_4seq1.xml · nonDerivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock"). F1 · price: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock"). Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:24 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 20,400 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001193125-26-064069 · ownership.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2036-02-19 F1 · derivative.exercise_date: The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 22:06 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 3,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-013038 · ownership.xml · nonDerivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,905 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 21:38 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | GrantRestricted Stock Units · Derivative | 94,050 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-125263 · tm2534450-9_4seq1.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,050 Underlying: Common Stock · 94,050 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"). The RSUs were awarded pursuant to the Company's 2025 Equity Incentive Plan for no consideration. F2 · derivative.exercise_date: The RSUs vested at issuance on December 23, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date. F2 · derivative.expiration_date: The RSUs vested at issuance on December 23, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:58 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | GrantRestricted Stock Units · Derivative | 74,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-111446 · tm2531210-8_4seq1.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,700 Underlying: Common Stock · 74,700 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"). The RSUs were awarded pursuant to the Company's 2022 Equity Incentive Plan for no consideration. F2 · derivative.exercise_date: The RSUs vested at issuance on November 11, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date. F2 · derivative.expiration_date: The RSUs vested at issuance on November 11, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:01 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 3,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-238982 · ownership.xml · nonDerivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,255 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 22:17 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-095403 · ownership.xml · nonDerivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,981 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| May 22, 2025 Filed May 23, 2025 21:03 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 19,111 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0000950170-25-077070 · ownership.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,111 Underlying: Common Stock · 19,111 shares Expires 2035-05-21 F1 · derivative.exercise_date: The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:57 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 3,065 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-053355 · ownership.xml · nonDerivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,231 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 23:42 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 3,166 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-139804 · ownership.xml · nonDerivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,166 F1 · shares: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:25 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001104659-24-106340 · tm2425653-7_4seq1.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-10-02 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 and for so long as the reporting person continues to be a director, consultant or service provider of the Company. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 21:56 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (Right to Buy) · Derivative | 64,503 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076369 · ownership.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,503 Underlying: Common Stock · 64,503 shares Expires 2034-06-18 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date. Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 02:34 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001104659-24-009023 · tm244775-12_4seq1.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-01-29 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:31 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001104659-23-095358 · tm2324823-4_4seq1.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-08-23 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of November 23, 2023, February 23, 2024, May 23, 2024 and August 23, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company. Read SEC document |
| June 07, 2023 Filed Jun 10, 2023 00:42 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 23,742 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0000899243-23-015313 · doc4.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,742 Underlying: Common Stock · 23,742 shares Expires 2033-06-06 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:12 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001104659-23-041746 · tm2311741-5_4seq1.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-03-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023 for so long as the reporting person continues to be a director, consultant or service provider of the Company until the Option is fully vested. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:22 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 10,362 | $0.00 Strike: $17.28 | $0.00 |
DisclosureSEC source: 0000899243-22-018290 · doc4.xml · derivative · entry 1 Martin Patricia A. · CIK 0001916764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,362 Underlying: Common Stock · 10,362 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/12 of the shares shall vest on each monthly anniversary as measured from March 25, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.